Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CHANDO Group
Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
JALA Group has successfully developed and commercialized 3D bioprinted Asian skin using bioprinting technology after 98 experiments[4][8]. The company has developed proprietary biotech platforms including plant cell tissue culture for rare plant extraction and microbial fermentation technology (HiMuchaSin), which reduces cosmetic raw material costs by 90% compared to imported alternatives[3].
- Therapeutic areas
- OtherDermatology
- Modalities
- Cell therapyBioprinting technologyPlant cell tissue cultureMicrobial fermentation
- Industry
- Non-Drug Biotech
02
Partnerships
LabSkin Creations (France)PoietisOrganovoCELLINK (bioprinting partners)China Environmental Protection FoundationJD.comTmallDouyin
Beyond the preview
Go deeper on CHANDO Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHANDO Group.